Member Info for tomvisual

£5B to be invested. Requirements at
https://ted.europa.eu/udl?uri=TED:NOTICE:263375-2020:TEXT:EN:HTML

Section II.2.4) may be of interest to the Avacta Affimer Therapeutic development!!! Imagine Govt funding!!
Description of the procurement:
To manufacture diagnostic or therapeutic products for the purpose of research, experimentation, study, development or to establish commercial viability or to recover research and development costs.

11.1.4 references mass spectrometry

Ophidian, thanks. Research closed.

Some conversion factors here perhaps??:
http://www.sciencegateway.org/protocols/cellbio/cell/moipfu.htm#:~:text=Plaque%20forming%20units%20(pfu)%20is,virus%20particles%20infecting%20each%20cell.&text=For%20example%2C%20if%202x106,of%20108%20pfu%2Fml
Or perhaps graphically from a response curve fir a particular virus as Ophidian advised!

RK, is there not two cost scenarios? One where control on covid had been achieved and one where it has not
if aditional outbreak waves occur the demand for PPE will also be astronomical again. Demand vs supply means cost of PPE rises. UKs reserves of PPE no doubt exhausted. Wondering what the Govt pandemic planming advisrs on replenishment!! Look at the US. Once this gets out of hand what cost would Govts pay? Economies will tank and unemployment rise again.
WHO advise this will get a lot worse.
Test, test, test was the advice at the outset. This advice will need to be heeded on a mass scale. Something that has not happened yet.

Sorcerer good summary.
Therapy partnership with a big pharma would also lay the foundation for affimers to be used in humans. Does partnership funding for a covid 19 therapeutic imply less funding/trials when developing affimers to address cancer?
Interesting.

The Pan, Zhang, Yang, Poon and Wang paper, although with results from only two people does have the encouraging remark,
'Sputum samples generally showed higher viral loads than throat swab samples.'
Direction of travel looks good so far to me!!

CO, taking a look at the Hong Kong Viral Load paper, the saliva samples are, 'posterior oropharyngeal (deep throat) saliva samples'.
I am wondering whether these are, in effect, the kind of throat samples that are taken with the throat part of the Nasopharyngeal test, which people don't like.
I am hoping that the saliva samples that the Avacta/Cytiva test uses are just the swilling around in the mouth type of saliva, rather than the deep throat variety. I think the Southampton study is on this basis.

From
https://www.hindustantimes.com/india-news/delhi-to-scale-up-rapid-antigen-testing/story-5kewDqMRxdSTwbeVFeKujJ.html
“The performance of the rapid antigen kits has been very good. Its specificity rate has been over 90% or so, which makes it an excellent tool to identify true positive cases. As a result, the number of people who actually need RT-PCR tests, which requires a high-grade testing lab, is much lower. With this, we won’t see a repeat of the phase we saw about a month back when people were finding it very difficult to get a Covid-19 test done because only RT-PCR kits were being used and the labs were overburdened with samples"
As I stated earlier on this BB, a Ferrari not a Rolls Royce PoC solution has been shown to have a massive impact on diagnosis of covid19 in India.
Hopefully, Avacta's Rolls Royce PoC test is only 2 weeks from design freeze. The impact of Avacta's test will be massive.
450INR is about £4.86.
Article mentions impact of PoC test on PCR test demand. Perhaps something to bear in mind if holding other covid stock when AVCT deliver?
Test, Test, Test

Filopodia highlighted in Daily Mail article
https://www.dailymail.co.uk/news/article-8466195/Pictured-Covid-19-hijacks-human-cells-causes-sprout-TENTACLES.html
Not enough information, as yet, to know how badly the filopodia finding complicates the search
for a vaccine, although it does not sound like good news.
Avacta may have to come up with an Affimer to deal with the filopodia, if the present ones don't do the trick.
Just as well Avacta state Affimers can be developed quickly!
Lets hope this stimulates a partnership deal.

Tansu, perhaps a question to as AS at a future webinar/presentation??

PAH00. Not impatient just looking at whats happening around the world. US and worldwide.
People are moving around and no instant testing is available.
RTC delayed antibody testing for werks. Todays announcement may have been overtaken by the relevance if antibody tests.
https://www.dailymail.co.uk/news/article-8459977/No-antibody-tests-good-use-outside-hospitals-review-finds.html
Whereas the bigger news article is impact of covid
https://www.dailymail.co.uk/news/article-8460145/Covid-19-lead-strokes-six-10-patients-hospitalised.html
Test, test, test has not truly happened!

PL75 ..
Time as they say is money.
I appreciate what Cytiva are trying to do. But witrth asking the question??
If the delay is minimal then more than happy to wait.
The question I am asking is what does the scientific community require? That should be the topic of debate amongst the scientific community and hence the requirement for regulatory approval. Perhaps the regulatory approval level is to low?
The presentation by AS set the baseline. But are we trying to provide a Rolls Royce solution when a Ferrari would be good enough??
We already have the 'Ferrari' implementation!!

According to modelling by the American economist Paul Romer, we really ought to be testing the whole population at least once a fortnight to be certain of where infections are taking place, and containing them appropriately. With such an infrastructure, no more than 10 per cent of the economy would need to be closed at any one time even if the so-called R rate was relatively high.
https://www.telegraph.co.uk/opinion/2020/06/26/testing-failures-leave-britain-shrouded-fear/

I have a few comments:
* I agree with Jeremy Warner's comments in the central importance of testing.
* A major slant of the article, although Jeremy Warner makes reference to conspiracy theories, makes me wonder if he does not subscribe to a few of the conspiracy theories himself.
* Lockdown and closing borders, as demonstrated by New Zealand and Australia, amongst others, are not a Chinese conspiracy - just the only effective method of handling Covid-19 that anyone has found so far - and epidemiologists are certainly trying, including Prof Ferguson and Anders Tegnell.
* If we had not locked down we would have reached where America seems to be heading.
* If Jeremy really does think there are other ways of handling Covid-19 perhaps he could enlighten people - although maybe he already has. Maybe you could see whether he has made some constructive comments in previous articles.
* very interesting points about how well the Chinese are recovering, as compared to the West.
* It would be interesting to see what Sensitivity and Specificity Prof Romer is now saying tests are required to have.
Prof Romer's model demonstrated that upper 90s % test Sensitivity is not needed to make a big favourable impact on Covid-19 control measures - 90% was extremely useful.
Does this actually mean that the LFT MK1 is actually good enough??? What actually does the scientific community require to control covid 19?
Is a Rolls Royce solution required???

I hope I am wrong but ....
Look at the chart.
This looks like a fake move to me.

I would have thought that the Avacta Affimer therapeutic might work in elderly people because, if I understand correctly, it does not require an immune response to be stimulated in the elderly person - rather, the therapeutic attaches to the Coronavirus spikes and this interferes with the docking of the spike with the cell ACE-2 receptor.
Another Avacta product that has the potential to have a massive impact, as long as it is safe and it is not like those other false hopes where there was no way to administer an adequate dose. Need the testing in the Ferrets or Mice to see what happens!

The medical community are waking-up to the dangers of 'normal' levels of inflammation in the elderly.
Covid-19 vaccine may not work for at-risk older people, say scientists
https://www.theguardian.com/world/2020/jun/23/covid-19-vaccine-may-not-work-for-at-risk-older-people-say-scientists
I would if Avacta's Affimer Therapeutic is a better option for the elderly??

Just emailed BBC R4 Today. Would encourage investors to spread the news!! Mass testing is now a reality.
Test, test, test

https://www.londonstockexchange.com/news-article/AVCT/update-on-covid-19-test-development-partnership/14588965

CautiousOptimist ...
Is 2% prevalence for general public high?
The Covid-19 app, estimates symptomatic Covid-19 on the IoW at 0.2%. Perhaps the same percentage again for asymptomatic Covid-19?
The highest I could find by clicking on the map in the app was 0.9% symptomatic Covid-19 in Newcastle Under Lyme, which would almost get to 2% for total cases.

Ophidan,
last slide Avactas test may be 90%/95% (Sensitivity/Specificity) at least. This will be better than present regulatory guidance and appropriate for a PoC general population test with prevalence for the general population at 2%.
Main point Cytiva prototype end of June, on TARGET!!!